Compare AEHL & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEHL | PPCB |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | China | Australia |
| Employees | N/A | 2 |
| Industry | Building Materials | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.9M |
| IPO Year | 2009 | N/A |
| Metric | AEHL | PPCB |
|---|---|---|
| Price | $0.51 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 285.1K | ★ 6.4M |
| Earning Date | 05-04-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.10 |
| 52 Week High | $6.53 | $10.69 |
| Indicator | AEHL | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 42.84 |
| Support Level | $0.48 | N/A |
| Resistance Level | $1.46 | $0.13 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.92 | 12.29 |
Antelope Enterprise Holdings Ltd operates in three reportable operating segments: Business Management Consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting; Natural Gas Power generation, which was in the initial development stage; and Live-Streaming e-commerce segment, providing a one-stop solution for customers to enable them to utilize the growing sales channel of livestreaming ecommerce. The business of the Company is engaged in the PRC and the United States.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.